The impact of adverse reactions on adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy in Japan.

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-09-12 DOI:10.1080/00016489.2024.2397054

Satoru Masuno

{"title":"The impact of adverse reactions on adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy in Japan.","authors":"Satoru Masuno","doi":"10.1080/00016489.2024.2397054","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nAllergen immunotherapy is the only treatment that can achieve remission for allergic diseases.\r\n\r\nAIMS/OBJECTIVES\r\nTo investigate the three-year adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy at a clinic in Japan and identify factors that influence adherence and severe adverse reactions.\r\n\r\nMATERIAL AND METHODS\r\nIn total, 174 patients aged 12 years or older who started sublingual immunotherapy for Japanese cedar pollinosis (n = 72), house dust mite allergy (n = 55), or both (n = 47) between May 2017 and June 2018. Patient age, sex, type of pharmacotherapy used, adverse reactions, blood test results, and duration of continuous treatment were investigated.\r\n\r\nRESULTS\r\nThe three-year treatment continuation rate was 40.8%. Adverse reaction rates were 12.6% for cedar pollinosis and 40.2% for house dust mite allergy. Patients with dose reductions due to severe reactions had lower first-year continuation rates. In the MITICURE® group, patients with severe reactions had significantly higher serum total IgE levels. Severe reactions were more common in MITICURE® patients with seven or more positive antigen types.\r\n\r\nCONCLUSIONS AND SIGNIFICANCE\r\nSevere adverse reactions reduced early adherence.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00016489.2024.2397054","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

BACKGROUND Allergen immunotherapy is the only treatment that can achieve remission for allergic diseases. AIMS/OBJECTIVES To investigate the three-year adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy at a clinic in Japan and identify factors that influence adherence and severe adverse reactions. MATERIAL AND METHODS In total, 174 patients aged 12 years or older who started sublingual immunotherapy for Japanese cedar pollinosis (n = 72), house dust mite allergy (n = 55), or both (n = 47) between May 2017 and June 2018. Patient age, sex, type of pharmacotherapy used, adverse reactions, blood test results, and duration of continuous treatment were investigated. RESULTS The three-year treatment continuation rate was 40.8%. Adverse reaction rates were 12.6% for cedar pollinosis and 40.2% for house dust mite allergy. Patients with dose reductions due to severe reactions had lower first-year continuation rates. In the MITICURE® group, patients with severe reactions had significantly higher serum total IgE levels. Severe reactions were more common in MITICURE® patients with seven or more positive antigen types. CONCLUSIONS AND SIGNIFICANCE Severe adverse reactions reduced early adherence.

查看原文本刊更多论文

在日本，不良反应对坚持使用舌下免疫疗法治疗杉树花粉症和屋尘螨过敏症的影响。

AIMS/OBJECTIVESTO 调查日本一家诊所对日本杉树花粉症和屋尘螨过敏舌下免疫疗法的三年坚持率，并确定影响坚持率和严重不良反应的因素。材料与方法在2017年5月至2018年6月期间，共有174名12岁或以上的患者开始舌下免疫疗法治疗日本杉树花粉症（n = 72）、屋尘螨过敏（n = 55）或两者（n = 47）。对患者的年龄、性别、使用的药物治疗类型、不良反应、血液检测结果和持续治疗时间进行了调查。结果三年治疗持续率为 40.8%。杉树花粉症的不良反应率为12.6%，屋尘螨过敏的不良反应率为40.2%。因严重反应而减少剂量的患者第一年的继续治疗率较低。在 MITICURE® 组中，严重反应患者的血清总 IgE 水平明显更高。严重不良反应降低了患者的早期依从性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.